Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA
Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated
Sydnexis sold the right to earn future money from a medicine called Ryjunea in Europe. This means Sydnexis got cash now, but Ligand will keep the profits from selling it there later.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.